JP2019535791A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019535791A5 JP2019535791A5 JP2019528540A JP2019528540A JP2019535791A5 JP 2019535791 A5 JP2019535791 A5 JP 2019535791A5 JP 2019528540 A JP2019528540 A JP 2019528540A JP 2019528540 A JP2019528540 A JP 2019528540A JP 2019535791 A5 JP2019535791 A5 JP 2019535791A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- subject
- risk
- reduce
- insulin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 claims 18
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 10
- 208000013016 Hypoglycemia Diseases 0.000 claims 5
- 108090001061 Insulin Proteins 0.000 claims 5
- 102000004877 Insulin Human genes 0.000 claims 5
- 230000002218 hypoglycaemic effect Effects 0.000 claims 5
- 229940125396 insulin Drugs 0.000 claims 5
- 229960004225 insulin degludec Drugs 0.000 claims 5
- 208000024172 Cardiovascular disease Diseases 0.000 claims 4
- FYZPCMFQCNBYCY-WIWKJPBBSA-N Insulin degludec Chemical compound CC[C@H](C)[C@H](NC(=O)CN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H]1CSSC[C@@H]2NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc3c[nH]cn3)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)Cc3ccccc3)C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](Cc3c[nH]cn3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC2=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H]([C@@H](C)O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC(O)=O)C(O)=O)C(O)=O)NC1=O)[C@@H](C)O)[C@@H](C)CC FYZPCMFQCNBYCY-WIWKJPBBSA-N 0.000 claims 4
- 108010050259 insulin degludec Proteins 0.000 claims 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 3
- 239000008103 glucose Substances 0.000 claims 3
- 238000012544 monitoring process Methods 0.000 claims 3
- 238000011282 treatment Methods 0.000 claims 3
- 230000002411 adverse Effects 0.000 claims 2
- 230000007211 cardiovascular event Effects 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 230000002641 glycemic effect Effects 0.000 claims 2
- 239000005022 packaging material Substances 0.000 claims 2
- 208000019553 vascular disease Diseases 0.000 claims 2
- 206010007558 Cardiac failure chronic Diseases 0.000 claims 1
- 206010052337 Diastolic dysfunction Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010049694 Left Ventricular Dysfunction Diseases 0.000 claims 1
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 claims 1
- 206010027525 Microalbuminuria Diseases 0.000 claims 1
- 208000018262 Peripheral vascular disease Diseases 0.000 claims 1
- 210000003423 ankle Anatomy 0.000 claims 1
- 239000003472 antidiabetic agent Substances 0.000 claims 1
- 229940125708 antidiabetic agent Drugs 0.000 claims 1
- 230000036772 blood pressure Effects 0.000 claims 1
- 208000026106 cerebrovascular disease Diseases 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims 1
- 238000002648 combination therapy Methods 0.000 claims 1
- 239000003877 glucagon like peptide 1 receptor agonist Substances 0.000 claims 1
- 238000011866 long-term treatment Methods 0.000 claims 1
- 239000003538 oral antidiabetic agent Substances 0.000 claims 1
- 230000002028 premature Effects 0.000 claims 1
- 201000001474 proteinuria Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 230000002861 ventricular Effects 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16200993.0 | 2016-11-28 | ||
| EP16200993 | 2016-11-28 | ||
| EP17162803 | 2017-03-24 | ||
| EP17162803.5 | 2017-03-24 | ||
| EP17174687 | 2017-06-07 | ||
| EP17174687.8 | 2017-06-07 | ||
| PCT/EP2017/080603 WO2018096163A1 (en) | 2016-11-28 | 2017-11-28 | Insulin degludec for improvement of glycaemic control and reduction of acute and long-term diabetes complications |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019535791A JP2019535791A (ja) | 2019-12-12 |
| JP2019535791A5 true JP2019535791A5 (https=) | 2020-12-17 |
Family
ID=60702634
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019528540A Withdrawn JP2019535791A (ja) | 2016-11-28 | 2017-11-28 | 血糖コントロールの改善並びに急性及び長期糖尿病合併症の低減のためのインスリンデグルデク |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11673933B2 (https=) |
| EP (1) | EP3544682A1 (https=) |
| JP (1) | JP2019535791A (https=) |
| CN (1) | CN110099719A (https=) |
| MA (1) | MA46890A (https=) |
| WO (1) | WO2018096163A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA46890A (fr) | 2016-11-28 | 2021-04-28 | Novo Nordisk As | Insuline degludec pour l'amélioration du contrôle glycémique et la réduction des complications du diabète aigu et à long terme |
| WO2018096162A1 (en) | 2016-11-28 | 2018-05-31 | Novo Nordisk A/S | Insulin degludec in cardiovascular conditions |
| AR112015A1 (es) | 2017-06-09 | 2019-09-11 | Novo Nordisk As | Composiciones sólidas para administración oral |
| US20230158234A1 (en) * | 2021-11-22 | 2023-05-25 | Colleen Cook | Method of Insulin Administration |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL128332A0 (en) | 1996-08-30 | 2000-01-31 | Novo Nordisk As | GLP-1 derivatives |
| GB0309154D0 (en) * | 2003-01-14 | 2003-05-28 | Aventis Pharma Inc | Use of insulin glargine to reduce or prevent cardiovascular events in patients being treated for dysglycemia |
| MXPA06001283A (es) | 2003-08-05 | 2006-04-11 | Novo Nordisk As | Derivados de insulina novedosos. |
| WO2013144273A1 (en) * | 2012-03-28 | 2013-10-03 | Sanofi | Basal insulin therapy |
| JP6755175B2 (ja) * | 2013-03-20 | 2020-09-16 | ノヴォ ノルディスク アー／エス | インスリン投薬レジメン |
| JP2016519127A (ja) * | 2013-04-30 | 2016-06-30 | ノヴォ ノルディスク アー／エス | 新規投与レジメン |
| MA46890A (fr) | 2016-11-28 | 2021-04-28 | Novo Nordisk As | Insuline degludec pour l'amélioration du contrôle glycémique et la réduction des complications du diabète aigu et à long terme |
-
2017
- 2017-11-28 MA MA046890A patent/MA46890A/fr unknown
- 2017-11-28 WO PCT/EP2017/080603 patent/WO2018096163A1/en not_active Ceased
- 2017-11-28 JP JP2019528540A patent/JP2019535791A/ja not_active Withdrawn
- 2017-11-28 CN CN201780073532.XA patent/CN110099719A/zh not_active Withdrawn
- 2017-11-28 EP EP17816532.0A patent/EP3544682A1/en not_active Withdrawn
- 2017-11-28 US US16/463,594 patent/US11673933B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Deacon | A review of dipeptidyl peptidase‐4 inhibitors. Hot topics from randomized controlled trials | |
| Jørgensen et al. | Exaggerated glucagon-like peptide 1 response is important for improved β-cell function and glucose tolerance after Roux-en-Y gastric bypass in patients with type 2 diabetes | |
| Raz | Guideline approach to therapy in patients with newly diagnosed type 2 diabetes | |
| Wysham et al. | Five-year efficacy and safety data of exenatide once weekly: long-term results from the DURATION-1 randomized clinical trial | |
| Carbone et al. | Glucose-lowering therapies for cardiovascular risk reduction in type 2 diabetes mellitus: state-of-the-art review | |
| Retnakaran et al. | Short‐term intensified insulin treatment in type 2 diabetes: long‐term effects on β‐cell function | |
| JP2019535791A5 (https=) | ||
| EA201590759A1 (ru) | Композиция для лечения диабета или диажирения, содержащая аналог оксинтомодулина | |
| Hanefeld | Use of insulin in type 2 diabetes: what we learned from recent clinical trials on the benefits of early insulin initiation | |
| HRP20221368T1 (hr) | Terapijske uporabe empagliflozina | |
| JP2020502151A5 (https=) | ||
| JP2020502150A5 (https=) | ||
| JP2019535785A5 (https=) | ||
| JP2020502140A5 (https=) | ||
| Ji | Treatment strategy for type 2 diabetes with obesity: focus on glucagon-like peptide-1 receptor agonists | |
| Chan et al. | Glycaemic responses in Asian and non-Asian people with type 2 diabetes initiating insulin glargine 100 units/mL: a patient-level pooled analysis of 16 randomised controlled trials | |
| Yabe et al. | Defining the role of GLP-1 receptor agonists for individualized treatment of type 2 diabetes | |
| Gallwitz | The future of combination therapies of insulin with a glucagon-like peptide-1 receptor agonists in type 2 diabetes–Is it advantageous? | |
| Buturovic et al. | Effects of teraphy with basal insulin analogues combined with GLP 1 analogues and metformin in the treatment of obese patients with poorly regulated postprandial glycemia | |
| Bodegard et al. | Second-line treatment with sulfonylurea compared to DPP4 inhibitors demonstrated associations with earlier treatment intensification with insulin | |
| Eriksson et al. | Second-line treatment with sulfonylurea compared to DPP4 inhibitors is associated with risk of cardiovascular disease, all-cause mortality and severe hypoglycaemia | |
| Schwarz | Inflammation as a factor of the pathogenesis of insulin resistance and type 2 diabetes | |
| Chattipakorn et al. | Dipeptidyl peptidase-4 inhibitors and the ischemic heart: additional benefits beyond glycemic control | |
| Ravindra et al. | Moving goal posts: definition of diabetes remission after bariatric surgery | |
| FORCE | AACE/ACE Comprehensive Diabetes Management Algorithm |